# Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

> **NCT07720596** · — · COMPLETED · sponsor: **Charles University, Czech Republic** · enrollment: 1795570 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT07720596
- **Lead sponsor:** Charles University, Czech Republic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 1795570 (ACTUAL)
- **Last updated:** 2026-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720596, "Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*